Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). With a standard 10-month review timeline, the FDA Prescription Drug User Fee Act (PDUFA) target action date is expected to occur in June 2012.

Related posts:

1. Dificid approvato, leggere attentamente le istruzioni…
2. Il Mercoledì di Cell Therapeutics. Pixantrone sarà approvato in Europa?
3. CBRX: approvazione di Prochieve e lo scandalo Makena.
4. Il 180° giorno di DYAX, nuovi farmaci in approvazione e altre storie.
5. CRIS, approvazione accelerata di Vismodegib.